Meanwhile, the UK launch of Freestyle Libre 3 comes as rival real-time CGM player Dexcom received a European CE mark for its G7 device for people with diabetes aged two years and older.

Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems, expanded reimbursement coverage, and a second-half launch of a 15-day G7 ...

Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.

SAN DIEGO - DexCom , Inc. (NASDAQ:DXCM) shares fell 6% in after-hours trading on Thursday after the continuous glucose monitoring systems maker reported fourth-quarter earnings that missed analyst ...

These are the kinds of stocks long-term investors will often be interested in, since they must have excellent, resilient ...

Dexcom stock tumbled late Thursday after the diabetes devices maker missed Wall Street's fourth-quarter profit expectations.

Persuade people with Type 1 diabetes to learn about the Dexcom G6 Continuous Glucose Monitor – overcoming low category/brand awareness. If people with T1D could choose any superpower, they'd choose ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...